Bacterial infections:
Indications for: FLAGYL 375
Susceptible anaerobic infections, including intraabdominal, skin and skin structures, gynecologic, bacterial septicemia, bone and joint, CNS, lower respiratory tract, endocarditis.
Adult Dosage:
7.5mg/kg every 6hrs for 7–10 days; max 4g/24hrs. Serious infections: parenteral form usually used first. Bone/joint, lower respiratory tract, endocardium infections: may need to treat longer. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.
Children Dosage:
Not established.
FLAGYL 375 Contraindications:
Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol or propylene glycol containing-products during or at least 3 days after treatment. Cockayne syndrome.
FLAGYL 375 Warnings/Precautions:
Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy. Nursing mothers: not recommended.
See Also:
FLAGYL 375 Classification:
Nitroimidazole.
FLAGYL 375 Interactions:
See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. Concomitant drugs with the potential for prolonging the QT interval; caution. May interfere with serum chemistry tests.
Adverse Reactions:
Nausea, headache, anorexia, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.
Drug Elimination:
-
Renal (60% to 80% of the dose), fecal (6% to 15%).
-
Half-life: 8 hours.
How Supplied:
Tabs—50, 100; Caps 375mg—50; IV—contact supplier
Protozoal infections:
Indications for: FLAGYL 375
Amebic dysentery. Amebic liver abscess.
Adult Dosage:
Give 3 times daily for 5–10 days. Dysentery: 750mg. Abscess: 500mg or 750mg. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.
Children Dosage:
35–50mg/kg/24hrs in 3 divided doses for 10 days. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.
FLAGYL 375 Contraindications:
Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol or propylene glycol containing-products during or at least 3 days after treatment. Cockayne syndrome.
FLAGYL 375 Warnings/Precautions:
Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy. Nursing mothers: not recommended.
See Also:
FLAGYL 375 Classification:
Nitroimidazole.
FLAGYL 375 Interactions:
See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. Concomitant drugs with the potential for prolonging the QT interval; caution. May interfere with serum chemistry tests.
Adverse Reactions:
Nausea, headache, anorexia, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.
Drug Elimination:
-
Renal (60% to 80% of the dose), fecal (6% to 15%).
-
Half-life: 8 hours.
How Supplied:
Tabs—50, 100; Caps 375mg—50
Vaginal infections:
Indications for: FLAGYL 375
Trichomoniasis.
Adult Dosage:
375mg twice daily for 7 days. Before repeating course, reconfirm diagnosis and allow 4–6 wks between courses. Treat consorts also. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.
Children Dosage:
Not established.
FLAGYL 375 Contraindications:
Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol or propylene glycol containing-products during or at least 3 days after treatment. Cockayne syndrome.
FLAGYL 375 Warnings/Precautions:
Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy. Nursing mothers: not recommended.
See Also:
FLAGYL 375 Classification:
Antiprotozoal/antibacterial.
FLAGYL 375 Interactions:
See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. Concomitant drugs with the potential for prolonging the QT interval; caution. May interfere with serum chemistry tests.
Adverse Reactions:
Nausea, headache, anorexia, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.
Drug Elimination:
-
Renal (60% to 80% of the dose), fecal (6% to 15%).
-
Half-life: 8 hours.
How Supplied:
Tabs—50, 100; ER—30; Caps 375mg—50
